Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.